clofarabine has been researched along with Lymphoma, Non-Hodgkin in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Borkhardt, A; Dilloo, D; Escherich, G; Faber, J; Feuchtinger, T; Horstmann, MA; Imschweiler, T; Jorch, N; Pekrun, A; Schmid, I; Schramm, F; Spohn, M; Zimmermann, M; Zur Stadt, U | 1 |
| Dreyling, M; Engel, N; Fritsch, S; Haas, M; Hausmann, A; Hellmuth, JC; Herold, T; Hiddemann, W; Hubmann, M; Ledderose, G; Mumm, F; Prevalsek, D; Reibke, R; Rieger, CT; Tischer, J; Zoellner, AK | 1 |
| Baiocchi, R; Blum, KA; Byrd, JC; Devine, SM; Hamadani, M; Johnson, AJ; Lin, TS; Lozanski, G; Lucas, DM; Phillips, GS; Porcu, P; Smith, LL | 1 |
| Nabhan, C | 1 |
| Cheson, BD; Friedberg, JW; Kahl, BS | 1 |
| Abonour, R; Baute, J; Cox, E; Farag, SS; Jones, D; Kane, K; Nelson, RP; Robertson, MJ; Schwartz, JE; Secrest, A; Srivastava, S; Sullivan, C; Wood, LL | 1 |
| Bitran, JD; Davis, N; Dewey, WM; Foss, S; Fried, W; Galvez, A; Nabhan, C; Tolzien, K; Venugopal, P | 1 |
| Artz, AS; Del Cerro, P; Godley, LA; Kline, J; Larson, RA; Nguyen, V; O'Donnell, PH; Odenike, O; Rich, E; Stock, W; van Besien, K | 1 |
| Abramson, JS; Barnes, JA; Brown, JR; Feng, Y; Fisher, DC; Hochberg, EP; Jacobsen, ED; Neuberg, DS; Takvorian, RW | 1 |
| Cheson, BD | 1 |
1 review(s) available for clofarabine and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Hematologic malignancies: new developments and future treatments.
Topics: Adenine Nucleotides; Alemtuzumab; Alkaloids; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cell Cycle; Cell Survival; Clofarabine; Cytosine; Dioxolanes; Flavonoids; Hematologic Neoplasms; Humans; Immunoconjugates; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Multiple Myeloma; NF-kappa B; Nitrogen Mustard Compounds; Oligonucleotides, Antisense; Peptide Hydrolases; Piperidines; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Remission Induction; Rituximab; Staurosporine; Thionucleotides | 2002 |
7 trial(s) available for clofarabine and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Clofarabine increases the eradication of minimal residual disease of primary B-precursor acute lymphoblastic leukemia compared to high-dose cytarabine without improvement of outcome. Results from the randomized clinical trial 08-09 of the Cooperative Acut
Topics: Acute Disease; Antineoplastic Agents; Child; Clofarabine; Cytarabine; Disease-Free Survival; Humans; Lymphoma, Non-Hodgkin; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Treatment Outcome | 2022 |
Sequential therapy combining clofarabine and T-cell-replete HLA-haploidentical haematopoietic SCT is feasible and shows efficacy in the treatment of refractory or relapsed aggressive lymphoma.
Topics: Adenine Nucleotides; Adult; Aged; Allografts; Antimetabolites, Antineoplastic; Arabinonucleosides; Clofarabine; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Retrospective Studies; Survival Rate | 2015 |
Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma.
Topics: Adenine Nucleotides; Aged; Arabinonucleosides; Clofarabine; Female; Hematopoiesis; Humans; Kinetics; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myeloablative Agonists; Neutropenia; Remission Induction; Salvage Therapy; Survival Analysis; Thrombocytopenia | 2009 |
A phase I trial of high-dose clofarabine, etoposide, and cyclophosphamide and autologous peripheral blood stem cell transplantation in patients with primary refractory and relapsed and refractory non-Hodgkin lymphoma.
Topics: Adenine Nucleotides; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Chemical and Drug Induced Liver Injury; Clofarabine; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Filgrastim; Gastrointestinal Diseases; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematopoietic Stem Cell Mobilization; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Recombinant Proteins; Recurrence; Salvage Therapy; Transplantation, Autologous; Treatment Outcome | 2011 |
Efficacy and safety of clofarabine in relapsed and/or refractory non-Hodgkin lymphoma, including rituximab-refractory patients.
Topics: Adenine Nucleotides; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Arabinonucleosides; Clofarabine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Retreatment; Rituximab; Salvage Therapy | 2011 |
Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation.
Topics: Acute Kidney Injury; Adenine Nucleotides; Adult; Age Factors; Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arabinonucleosides; Clofarabine; Female; Glomerular Filtration Rate; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Recurrence; Risk; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous | 2012 |
Oral clofarabine for relapsed/refractory non-Hodgkin lymphomas: results of a phase 1 study.
Topics: Adenine Nucleotides; Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Arabinonucleosides; CD4 Lymphocyte Count; Clofarabine; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Remission Induction; Treatment Outcome; Tumor Burden | 2013 |
2 other study(ies) available for clofarabine and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Clofarabine in relapsed lymphoma: what is the optimal dose?
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Clinical Trials as Topic; Clofarabine; Data Interpretation, Statistical; Drug Administration Schedule; Humans; Lymphoma, Non-Hodgkin; Medical Oncology; Recurrence; Remission Induction; Research Design | 2009 |
Clinical Roundtable Monograph: current treatment options for NHL patients refractory to standard therapy: recent data in single-agent and combination therapy.
Topics: Adenine Nucleotides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Bendamustine Hydrochloride; Clofarabine; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Phosphoinositide-3 Kinase Inhibitors; Rituximab; Thalidomide | 2010 |